Institution
Saint Luke's Hospital
Recent research
- Health & Medicine
Background: Despite the use of atrial fibrillation (AF) cutoff of 30s as the standard for success in most AF clinical trials, patients consider an AF Severity Scale (AFSS) of ≤ 5 or AF duration ≤ 1 hour as treatment success. Prevalence and factors associated with these patient-de...
- Society & Economics
Weighted Blankets to Reduce Anxiety in Hospitalized Patients
Background Weighted blankets are used to help bring calm and promote sleep. Research has shown that the use of weighted blankets can alleviate stress and anxiety, but studies have not been conducted in acutely ill, hospitalized patients. Objective To determine the effectiveness o...
- Health & Medicine
Remote Monitoring Devices and Heart Failure.
Remote patient monitoring (RPM) in patients with heart failure (HF) involves transmitting physiological data from devices to a health-care provider via a wireless connection with targeted interventions when values exceed the preset threshold. Devices used in telemonitoring range...
- Health & MedicineOpen access
BACKGROUND: Aficamten significantly improved both functional capacity and patient-reported health status in patients with symptomatic nonobstructive hypertrophic cardiomyopathy in the phase 3 randomized, placebo-controlled ACACIA-HCM trial (Assessment Comparing Aficamten to Place...
- Health & MedicineOpen access
Global Efficacy of Aficamten in Nonobstructive Hypertrophic Cardiomyopathy: Results From ACACIA-HCM
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (nHCM) is associated with significant morbidity with no approved treatment. Aficamten is a cardiac myosin inhibitor targeting excess contractility and diastolic impairment, the predominant mechanism responsible for adverse ou...
- Health & Medicine
Aficamten for Symptomatic Nonobstructive Hypertrophic Cardiomyopathy
BACKGROUND: Nonobstructive hypertrophic cardiomyopathy (HCM) is a common condition that is associated with substantial morbidity and no proven medical therapy. Whether treatment with aficamten, a cardiac myosin inhibitor, can benefit patients with this condition is unknown. METHO...